Rejigged deal gives Schering-Plough Japan taribavirin option
This article was originally published in Scrip
Valeant Pharmaceuticals International has granted Schering-Plough an exclusive option to acquire sole development and commercialisation rights in Japan to its antiviral candidate taribavirin.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.